Also known as: Pitocin (IV) · Syntocinon (intranasal) · OXT
| Parameter | IV (Pitocin) | Intranasal | Source |
|---|---|---|---|
| Elimination Half-Life | ~1–6 min | ~30 min (plasma) | FDA Pitocin label; PMID 22903776 |
| Tmax | Immediate | ~30–60 min | FDA Pitocin label; PMID 22903776 |
| Bioavailability | 100% (IV by definition) | ~12–18% (plasma); CNS route additional | Research data; PMID 23867355 |
| Full Clearance (5 half-lives) | ~5–30 min | ~150 min (2.5 h) | Calculated |
| CNS Effect Duration (intranasal) | N/A | ~60–90 min (behavioral) | PMID 22903776 |
| Standard Dosing (IV) | 10–40 mU/min infusion for labour | Off-label; 10–24 IU PRN intranasal | FDA Pitocin label |
| Data Quality | Human PK Study — FDA Pitocin label; Neumann ID, Landgraf R. Nat Rev Neurosci 2012 PMID 22903776 | ||
Oxytocin's half-life is entirely route-dependent, making it one of the most pharmacokinetically variable compounds in clinical and research use. Intravenous oxytocin (Pitocin) has a plasma half-life of approximately 1–6 minutes per the FDA-approved prescribing information.[1] Intranasal oxytocin has a substantially longer plasma half-life of approximately 30 minutes, based on human pharmacokinetic data from published studies.[2]
Oxytocin is a nonapeptide (nine amino acids: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂, with a disulfide bridge between positions 1 and 6) produced endogenously by the paraventricular and supraoptic nuclei of the hypothalamus. As an endogenous hormone with a native plasma half-life of 1–6 minutes (IV), it is cleared primarily by oxytocinase (cystyl aminopeptidase), placental leucine aminopeptidase, and renal excretion.
Oxytocin's plasma half-life and its CNS (central nervous system) pharmacological effect duration are partially independent. This is a unique property of oxytocin not shared by most small-molecule drugs. The hypothalamus releases oxytocin into the brain via axonal projections independent of peripheral plasma concentrations — central and peripheral oxytocin pools do not equilibrate rapidly.[2]
Intranasal oxytocin achieves direct CNS penetration via olfactory and trigeminal nerve pathways, reaching the cerebrospinal fluid (CSF) independently of peripheral plasma levels. Human studies have documented elevated CSF oxytocin following intranasal administration, with behavioral effects (bonding, anxiety reduction, social cognition) persisting up to 60–90 minutes post-dose despite plasma half-life of ~30 minutes.[3]
| Half-Lives Elapsed | Time After Stopping Infusion | % Remaining in Plasma | Clinical Note |
|---|---|---|---|
| 1 | ~1–6 min | 50% | Uterine contractions begin to diminish |
| 2 | ~2–12 min | 25% | Rapid clinical effect reversal |
| 3 | ~3–18 min | 12.5% | Most uterotonic effect dissipating |
| 4 | ~4–24 min | 6.25% | Near clearance |
| 5 (clinical clearance threshold) | ~5–30 min | ~3% | Pharmacologically negligible; infusion can be titrated rapidly |
| Half-Lives Elapsed | Time After Intranasal Dose | % Remaining in Plasma | Clinical Note |
|---|---|---|---|
| 1 | ~30 min | 50% | Within peak CNS behavioral effect window |
| 2 | ~60 min | 25% | Behavioral effects (anxiety, social cognition) typically ongoing |
| 3 | ~90 min | 12.5% | CNS effects beginning to wane |
| 4 | ~120 min | 6.25% | Near-complete plasma clearance |
| 5 (clinical clearance threshold) | ~150 min (2.5 h) | ~3% | Pharmacologically negligible plasma level |
CNS behavioral effects outlast plasma clearance. For intranasal oxytocin, documented behavioral effects (bonding, anxiety reduction) can persist 60–90 minutes after dosing — longer than the ~30-minute plasma half-life — due to direct CSF delivery via olfactory/trigeminal pathways that bypasses plasma compartment kinetics.[2][3]
The ~1–6 minute IV half-life is the basis for oxytocin being administered as a continuous IV infusion (10–40 mU/min) rather than bolus injection for labour induction. The extremely short half-life allows precise titration — if uterine hyperstimulation occurs, stopping the infusion produces rapid plasma clearance within 5–30 minutes, reversing the effect. This is a pharmacokinetic safety feature of the IV route.[1]
For research into behavioral effects of oxytocin (social bonding, anxiety, trust), the intranasal route is preferred specifically because it achieves direct CNS access via olfactory pathways — bypassing the blood-brain barrier that limits peripheral IV oxytocin's central effects. The ~30-minute plasma half-life intranasal is substantially longer than IV, and the direct CNS delivery extends behavioral effect duration to ~60–90 minutes per dose.[2]
| Compound | Route | Half-Life | Primary Use | Status |
|---|---|---|---|---|
| Oxytocin IV (Pitocin) | IV infusion | ~1–6 min | Labour induction | FDA-approved |
| Oxytocin intranasal | Intranasal spray | ~30 min (plasma); effects ~60–90 min | Research (bonding, anxiety, autism) | Not FDA-approved in US |
| PT-141 (bremelanotide) | SC injection | ~2.7 h | HSDD in premenopausal women | FDA-approved NDA 210557 |
| Vasopressin (ADH) | IV / SC / intranasal | ~20 min (IV) | Diabetes insipidus, vasodilatory shock | FDA-approved (Vasostrict IV) |
| Route | Half-Life | Bioavailability | Tmax | Notes |
|---|---|---|---|---|
| Intravenous | ~1–6 min | 100% | Immediate | FDA-approved (Pitocin); precise titration possible; standard for labour induction |
| Intranasal | ~30 min (plasma); behavioral effects ~60–90 min | ~12–18% plasma; CNS additional via olfactory route | ~30–60 min | Not FDA-approved in US; research use under IND |
| Intramuscular | ~15–30 min (estimated) | High (estimated) | ~15–30 min | Used clinically for postpartum haemorrhage prevention in some protocols; less precise than IV |
| Subcutaneous | No published human data | No published data | No published data | Not a standard or approved route |
| Oral | Not viable | <1% (estimated) | — | Oxytocinase and GI proteases degrade the peptide before absorption |
Oxytocin is an endogenous hormone naturally present in human plasma and urine. It is not included in any standard WADA or workplace drug test panel. Distinguishing exogenous from endogenous oxytocin using standard immunoassay is not reliable. No forensic detection panel has been established for exogenous oxytocin.
Research-grade oxytocin assays (ELISA, RIA) can quantify plasma and CSF oxytocin levels, but these are not validated for forensic purposes and cannot reliably distinguish exogenous from endogenous sources. Given IV half-life of 1–6 minutes, plasma would clear to near-baseline within 30 minutes of stopping an IV infusion; intranasal administration would clear within ~2.5 hours.
Oxytocin (MW ~1,007 Da) is a nonapeptide with a disulfide bridge that confers some structural stability but does not prevent rapid enzymatic degradation in plasma. The primary clearance enzyme is oxytocinase (cystyl aminopeptidase, also called leucyl-cystinyl aminopeptidase / LNPEP), which cleaves the Cys1-Tyr2 bond, opening the ring structure and inactivating the peptide. Additional clearance occurs via renal filtration (the ~1,007 Da MW is below the glomerular threshold) and hepatic metabolism.[1]
The ~1–6 minute IV half-life is a consequence of the absence of plasma protein binding (oxytocin is not albumin-bound), continuous oxytocinase activity in plasma, and the small molecular size favoring rapid renal filtration. Intranasal administration bypasses the immediate plasma oxytocinase exposure, allowing a longer effective half-life of ~30 minutes in plasma and independent CNS delivery via olfactory nerve axonal transport.[2]
Log oxytocin doses and route, track your intranasal timing against the ~30-minute plasma half-life and ~60–90 minute behavioral effect window. On-device, no account required.
Download Free — iOS